Skip to content

To construct stratified prognostic and stratified treatment strategies for head and neck squamous cell carcinoma patients based on multi-omics data

To construct stratified prognostic and stratified treatment strategies for head and neck squamous cell carcinoma patients based on multi-omics data

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080021
Enrollment
Unknown
Registered
2024-01-18
Start date
2024-02-05
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck squamous cell carcinoma

Interventions

head and neck squamous cell carcinoma group:NA

Sponsors

Eye & ENT Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Able to understand and willing to sign a written informed consent document. 2. Pathologically diagnosed with squamous cell carcinoma of head and neck. 3. Age = 18 4. Male or female. 5. Hepatic function, renal function and normal blood test. Hepatic function: Alanine aminotransferase (ALT) = 2.5 upper limit of normal, Aspartate aminotransferase (AST) = 2.5 upper limit of normal. Serum total bilirubin = 1.5 upper limit of normal. Kidney function: Serum creatinine 60 ml/(min*1.73m2) (Cockcroft-Gault formula). Blood test: neutrophil (Neu) = 1.5×109/L, platelet (PLT) = 100×109/L, hemoglobin (HGB) = 90 g/L. 6. Good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients who have participated in other clinical trials within 1 month before the test. 2. The investigator believes that it is inappropriate for individuals to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time [within the past year] or active suicidal ideation or behavior). 3. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Transcriptome characteristics;Metabolome characteristics;Genomic characteristics;Epigenetic characteristics;

Secondary

MeasureTime frame
Proteome characteristics;Microbiome characteristics;Temporal and spatial transcriptome characteristics;Spatiotemporal metabolome characteristics;Characteristics of immune microenvironment;

Countries

China

Contacts

Public ContactMing Zhang

Eye & ENT Hospital, Fudan University

ent_zhm@126.com+86 64377151

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026